PCSK9 inhibition was initially approved in 2015 for adult patients with hyperlipidemia and in 2017 for people with cardiovascular disease and increased risk for myocardial infarction, stroke, and revascularization in atherosclerotic cardiovascular disease [117,118,119,120]. Here, PCSK9 is linked to myocardial infarction.